



Program Agenda

DAY 1 THURSDAY – FEBRUARY 1, 2018		
2:00-2:10pm	Welcome and introduction	Owen A. O'Connor
2:10-2:15	Introduction of keynote presenter	Owen A. O'Connor
2:15-3:00	Keynote address: A journey through 3 decades of PTCL evolution: A clinicians' viewpoint on where we are going	Christian Gisselbrecht
SESSION 1: Epidemiology		
Moderators:	Thomas Waldmann; WS Kim	
3:05-3:20	Classification	Pier Paolo Piccaluga
3:25-3:40	Swedish Lymphoma Registry	Thomas Relander
3:45-4:00	Nasal NK relapsed after SMILE...What to do next	HQ Huang
4:05-4:20	Molecular classifiers of PTCL: Are TBX-21/GATA3 the ticket?	Ryan Wilcox
4:25-4:40	BREAK	
SESSION 2: Pathology		
Moderators:	Pier Paolo Piccaluga; Christian Gisselbrecht	
4:45-5:00	Mouse models to study the pathogenesis of ALCL	Giorgio Inghirami
5:05-5:20	The role of RHOA mutations in T-cell lymphomas	Sakata Yanagimoto
5:25-5:40	Update on ALCL pathogenesis	Andrew Feldman
5:45-6:05	Building a human T or NK cell lymphoma model in vitro	John Chan
6:05-9:00	Welcome Dinner	
DAY 2 FRIDAY – FEBRUARY 2, 2018		
7:00-8:00am	Breakfast Symposium	
8:30-8:35	Day 2 opening remarks:	Francine Foss
SESSION 3: CTCL		
Moderators:	Madeline Duvic; Nora Bennani	
8:35-8:50	The evolving immunological milieu in CTCL	Alain Rook
8:55-9:10	Photopheresis- The next generation immunotherapy	Richard Edelson
9:15-9:30	Targeting p38 gamma in T cell lymphomas	Steve Rosen
9:35-9:50	Emerging rationale for targeting miRNA's in CTCL	Christiane Querfeld
9:55-10:10	Targeting KIR3DL2 in CTCL	Youn Kim
10:15-10:30	BREAK	
SESSION 4: Molecular Pathways		
Moderators:	Steve Ansel; Giorgio Inghirami	
10:30-10:45	Emerging role of microenvironment in T-cell	Nora Bennani
10:50-11:05	Evolving therapies for the large granulocytic leukemias	Thomas Loughran
11:10-11:25	New technologies in identifying genetic signatures in T-cell	Sandeep Dave
11:30-11:45	Contemplating the role of JAK/STAT signaling in TCL	Thomas Waldmann
12:30-1:30 pm	Lunch Symposium	
2:00-2:15	Announcement of TCLLF Research Grant Sponsorship Winner	Toni-Ann Lupinacci



SESSION 5: Case Presentations

Moderators:	Youn Kim; Francine Foss		
2:20-2:45	Tumor stage and transformed MF	Fellow	Foss
2:45-3:10	LGL patients who failed methotrexate: What next?	Jeffrey Xing	Loughran
3:10-3:35	Managing relapsed PTCL in non-transplant candidate	Thais Fischer	Chiatton
3:35-4:00	Relapsed PTCL: Are there new agents to be considered?	Matthew Cross	Dearden
4:05-4:20	BREAK		

SESSION 6: Poster presentations

Moderators:	Ahmed Sawas; Christiane Querfeld		
4:20-4:30	1. PI3	Oki	
4:32-4:42	2. Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve by Distinct Genetic Pathways	Tayla Heavican	
4:44-4:54	3. A phase 1/2 study of oral 5-azacitidine and romidepsin in patients with lymphoid malignancies shows promising activity in peripheral T-cell lymphoma	Lorenzo Falchi	
4:46-5:06	4. Exploiting novel mechanisms of PDL-1 regulation using high-throughput CRISPR screen in Anaplastic large-cell lymphoma	Yibin Yang	
5:08-5:18	5. Comparison of prognostic scores in peripheral T-cell lymphoma	Sung Yong Oh	
5:20-5:30	6. Role of FDG PET for evaluation of bone marrow status and prognosis prediction in T-cell lymphomas	Youngil Koh	
5:20-5:30	7. Phase I Study of Y90-Basiliximab Plus BEAM for ASCT in Patients with Mature T-Cell Lymphomas: The "aTAC-BEAM Regimen"	Jasmine Zain	
5:32-5:42	8. Frequent genomic alterations in young patients with adult T-cell leukemia/lymphoma.	Noriaki Yoshida	
5:44-5:54	9. RP6530, a dual PI3K δ/γ inhibitor: Interim results of a Phase I/Ib Study in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma	Ajit Nair	
6:00-8:00	Poster Walk Reception		

DAY 3 SATURDAY – FEBRUARY 3, 2018

7:00-8:00am	Continental Breakfast		
8:10-8:15am	Day 3 opening remarks:	Won Seog Kim	

SESSION 7: Updates in Therapeutic Management

Moderators:	Owen O'Connor; Lorenz Trümper		
8:15-8:30	Identifying the best bridge to transplant with new agents	Steven Horwitz	
8:35-8:50	Transplant strategies in lymphomas	Soon Thye Lim	
8:55-9:10	Emerging targets and opportunities for CAR-T in T-cell	Andrei Shustov	
9:15-9:30	PD-1/PD-L1 as a target in NK T-cell: From biology to treatment	YL Kwong	
9:35-9:50	What's on the horizon in new therapies in T-cell	Ahmed Sawas	
9:55-10:10	Deciphering the role of PI3 inhibitors in T-cell lymphomas: the good, the bad, the future	Pier Luigi Zinzani	
10:15-10:30	What is the role for EZH2 inhibitors in T-cell Lymphoma	Kunihiro Tsukasaki	
10:35-10:50	Immuno-oncology opportunities in T-cell	Lorenz Trümper	
10:55-11:10	How I treat ATL	Ali Bazarbachi	
11:15-11:25	BREAK		



SESSION 8: Regulatory Insights: Moving the Field Forward

Moderators: Francine Foss; Won Seog Kim; Owen O'Connor

11:25-11:40	Accelerating Drug Development in T-cell Lymphoma	Angelo De Claro
11:45-12:00pm	Global T-cell Consortium	Owen O'Connor
12:05-12:20	Case Match Control	Enrica Marchi
12:25-12:40	OPD in T-cell	Katherine Needleman

SESSION 9: Wrap-up Highlights

Moderators: Francine Foss; Won Seog Kim; Owen O'Connor

12:45-12:55	Summary perspective on CTCL	Madeleine Duvic
12:55-1:05	Summary perspective on molecular pathogenesis	Pier Paolo Piccaluga
1:05-1:15	Summary perspective on evolving treatments for PTCL	Barbara Pro
1:15-1:25	Closing remarks	Won Seog Kim
1:25	Adjourn—Box lunch	